Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Neurology
Published in: Current Treatment Options in Neurology 8/2019

01-08-2019 | Care | Neuromuscular Disorders (C Fournier, Section Editor)

Interprofessional Care for Neuromuscular Disease

Authors: Ileana Howard, MD, Abigail Potts, MS, CCC-SLP

Published in: Current Treatment Options in Neurology | Issue 8/2019

Login to get access

Abstract

Purpose of review

This review aims to delineate interprofessional care models for neuromuscular disease. Evidence regarding both the benefits and barriers to interprofessional neuromuscular care in both inpatient and outpatient settings is presented. Finally, opportunities to improve both access to and quality of care provided by interprofessional team clinics will be discussed.

Recent findings

Although the term “multidisciplinary” is often misapplied to denote any interprofessional team-based care setting, there are important differences in team structure and dynamics in each of the three most common models: multidisciplinary, interdisciplinary, and transdisciplinary care. Evidence favors the more integrated interdisciplinary and transdisciplinary models for better patient outcomes and decreased staff burnout. Coordinated interprofessional care results in improved health outcomes, resource utilization, and patient satisfaction for persons with adult and pediatric neuromuscular disease. Distance remains the greatest barrier to specialized team-based care for this population; telehealth technologies may make interprofessional care more accessible to these persons.

Summary

Despite limited evidence for the broader population of persons with neuromuscular disease, consensus guidelines increasingly support this model of care delivery. Further work may help determine effectiveness for other populations of persons with neuromuscular disease and best practices within these team-based models of care.
Literature
1.
•• Nicholson K, Murphy A, McDonnell E, et al. Improving symptom management for people with amyotrophic lateral sclerosis. Muscle Nerve. 2018;57:20–4 This questionnaire-based study confirms the high secondary symptom burden in the ALS population, and demonstrates how clinicians most often fail to manage these symptoms.CrossRef
2.
Chaney JM, Mullins L. A systems and social cognitive approach to team functioning in physical rehabilitation settings. Rehabil Psychol. 1994;39:161–78.CrossRef
3.
Wagner KN, Nagaraja HN, Allain DC, Quick A, Kolb SJ, Roggenbuck J. Patients with sporadic and familial amyotrophic lateral sclerosis found value in genetic testing. Mol Genet Genomic Med. 2018;6:224–9.CrossRef
4.
Bello-Haas V. A framework for rehabilitation of neurodegenerative diseases: planning care and maximizing quality of life. J Neurol Phys Ther. 2002;26:115–29.
5.
Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22:1027–49.CrossRef
6.
•• Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:251–67 These clinical practice guideline provide an excellent example of clear delineation of roles of the interprofessional team in the management of a complex neuromuscular population which could be extrapolated to the care of persons with other disorders.CrossRef
7.
Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1227–33.CrossRef
8.
Narayanaswami P, Carter G, David W, Weiss M, Amato AA. Evidence-based guideline summary: diagnosis and treatment of limb-girdle and distal dystrophies: report of the guideline development subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology. 2015;84:1720–1.CrossRef
9.
Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010;17:356–63.CrossRef
10.
Ashizawa T, Gagnon C, Groh WJ, et al. Consensus-based care recommendations for adults with myotonic dystrophy type 1. Neurol Clin Pract. 2018;8:507–20.CrossRef
11.
Kortebein P, Granger CV, Sullivan DH. A comparative evaluation of inpatient rehabilitation for older adults with debility, hip fracture, and myopathy. Arch Phys Med Rehabil. 2009;90:934–8.CrossRef
12.
Gomez Fernandez L, Calzada Sierra DJ. The importance of multifactorial rehabilitation treatment in amyotrophic lateral sclerosis. Rev Neurol. 2001;32:423–6.PubMed
13.
Ng L, Khan F, Mathers S. Multidisciplinary care for adults with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev. 2009:CD007425.
14.
Chio A, Bottacchi E, Buffa C, Mutani R, Mora G. Parals. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry. 2006;77:948–50.CrossRef
15.
O’Brien MR, Whitehead B, Jack BA, Mitchell JD. From symptom onset to a diagnosis of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND): experiences of people with ALS/MND and family carers - a qualitative study. Amyotroph Lateral Scler. 2011;12:97–104.CrossRef
16.
Hogden A, Greenfield D, Nugus P, Kiernan MC. What influences patient decision-making in amyotrophic lateral sclerosis multidisciplinary care? A study of patient perspectives. Patient Prefer Adherence. 2012;6:829–38.CrossRef
17.
Lopez-Gomez JJ, Torres-Torres B, Gomez-Hoyos E, et al. Influence of a multidisciplinary protocol on nutritional status at diagnosis in amyotrophic lateral sclerosis. Nutrition. 2018;48:67–72.CrossRef
18.
Shanafelt TD, Hasan O, Dyrbye LN, et al. Changes in burnout and satisfaction with work-life balance in physicians and the general US working population between 2011 and 2014. Mayo Clin Proc. 2015;90:1600–13.CrossRef
19.
Bromberg MB, Schenkenberg T, Brownell AA. A survey of stress among amyotrophic lateral sclerosis care providers. Amyotroph Lateral Scler. 2011;12:162–7.CrossRef
20.
Aho-Ozhan HE, Bohm S, Keller J, et al. Experience matters: neurologists’ perspectives on ALS patients’ well-being. J Neurol. 2017;264:639–46.CrossRef
21.
Cup EH, Pieterse AJ, Hendricks HT, van Engelen BG, Oostendorp RA, van der Wilt GJ. Implementation of multidisciplinary advice to allied health care professionals regarding the management of their patients with neuromuscular diseases. Disabil Rehabil. 2011;33:787–95.CrossRef
22.
van der Steen I, van den Berg JP, Buskens E, Lindeman E, van den Berg LH. The costs of amyotrophic lateral sclerosis, according to type of care. Amyotroph Lateral Scler. 2009;10:27–34.CrossRef
23.
Jefferies KA, Bromberg MB. The role of a clinical pharmacist in a multidisciplinary amyotrophic lateral sclerosis clinic. Amyotroph Lateral Scler. 2012;13:233–6.CrossRef
24.•
Horton DK, Graham S, Punjani R, et al. A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and their proximity to multidisciplinary ALS clinics, 2013. Amyotroph Lateral Scler Frontotemporal Degener. 2017:1–8 Provides objective evidence for the geographic barriers between persons with ALS and specialty interprofessional clinics. This relates well to the subjective feedback from patients regarding difficulty accessing clinics due to distance in the questionnaire-based studies also referenced in this paper.
25.
Stephens HE, Young J, Felgoise SH, Simmons Z. A qualitative study of multidisciplinary ALS clinic use in the United States. Amyotroph Lateral Scler Frontotemporal Degener. 2015;17:55–61.CrossRef
26.
• Schellenberg KL, Hansen G. Patient perspectives on transitioning to amyotrophic lateral sclerosis multidisciplinary clinics. J Multidiscip Healthc. 2018;11:519–24 This is the first known study that solicited patient perspectives/input during the design phase of building a multidisciplinary clinic to care for ALS in Canada. Of note, the majority of respondents recommended incorporating emotional support for both patients and caregivers into the design of the clinic.CrossRef
27.
Boylan K, Levine T, Lomen-Hoerth C, et al. Prospective study of cost of care at multidisciplinary ALS centers adhering to American Academy of Neurology (AAN) ALS practice parameters. Amyotroph Lateral Scler Frontotemporal Degener. 2015;17:119–27.CrossRef
28.
•• Paganoni S, Nicholson K, Leigh F, et al. Developing multidisciplinary clinics for neuromuscular care and research. Muscle Nerve. 2017;56:848–58 Excellent discussion regarding cost, outcomes, and value of multidisciplinary clinical management in neuromuscular disease. Of particular emphasis is the role of the multidisciplinary team in management of pediatric disorders, and the emerging potential of technology in expanding access to care.CrossRef
29.
Gladman M, Dharamshi C, Zinman L. Economic burden of amyotrophic lateral sclerosis: a Canadian study of out-of-pocket expenses. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:426–32.CrossRef
30.
Meng L, Bian A, Jordan S, Wolff A, Shefner JM, Andrews J. Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:134–42.CrossRef
31.
Pearl PL, Sable C, Evans S, et al. International telemedicine consultations for neurodevelopmental disabilities. Telemed J E Health. 2014;20:559–62.CrossRef
32.
Savard L, Borstad A, Tkachuck J, Lauderdale D, Conroy B. Telerehabilitation consultations for clients with neurologic diagnoses: cases from rural Minnesota and American Samoa. NeuroRehabilitation. 2003;18:93–102.PubMed
33.
Bashiri M, Greenfield LJ Jr, Oliveto A. Telemedicine interest for routine follow-up care among neurology patients in Arkansas. Telemed J E Health. 2016;22:514–8.CrossRef
34.
Geronimo A, Wright C, Morris A, Walsh S, Snyder B, Simmons Z. Incorporation of telehealth into a multidisciplinary ALS Clinic: feasibility and acceptability. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:555–61.CrossRef
35.
Nijeweme-d’Hollosy WO, Janssen EP. Huis in ‘t Veld RM, Spoelstra J, Vollenbroek-Hutten MM and Hermens HJ. Tele-treatment of patients with amyotrophic lateral sclerosis (ALS). J Telemed Telecare. 2006;12(Suppl 1):31–4.CrossRef
36.
Pinto A, Almeida JP, Pinto S, Pereira J, Oliveira AG, de Carvalho M. Home telemonitoring of non-invasive ventilation decreases healthcare utilisation in a prospective controlled trial of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2010;81:1238–42.CrossRef
37.
Hobson EV, Baird WO, Cooper CL, Mawson S, Shaw PJ, McDermott CJ. Using technology to improve access to specialist care in amyotrophic lateral sclerosis: a systematic review. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:313–24.CrossRef
Metadata
Title
Interprofessional Care for Neuromuscular Disease
Authors
Ileana Howard, MD
Abigail Potts, MS, CCC-SLP
Publication date
01-08-2019
Publisher
Springer US
Published in
Current Treatment Options in Neurology / Issue 8/2019
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-019-0576-z

Other articles of this Issue 8/2019

Current Treatment Options in Neurology 8/2019 Go to the issue

Dementia (J Pillai, Section Editor)

Diagnosis and Management of Autonomic Dysfunction in Dementia Syndromes

Neuro-oncology (R Soffietti, Section Editor)

Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials

Neuro-oncology (R Soffietti, Section Editor)

Treatment of Primary Central Nervous System Lymphoma in Immunocompetent Patients

Neurologic Ophthalmology and Otology (R Shin and D Gold, Section Editors)

Treatment Strategies for Neuroretinitis: Current Options and Emerging Therapies

Critical Care Neurology (H Hinson, Section Editor)

Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment